Warfarin Pharmacogenetics: CYP2C9 and VKORC1 Genotypes Predict Different Sensitivity and Resistance Frequencies in the Ashkenazi and Sephardi Jewish Populations
- 1 February 2008
- journal article
- research article
- Published by Elsevier in American Journal of Human Genetics
- Vol. 82 (2), 495-500
- https://doi.org/10.1016/j.ajhg.2007.10.002
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- A new vitamin K epoxide reductase complex subunit‐1 (VKORC1) mutation in a patient with decreased stability of CYP2C9 enzymeJournal of Thrombosis and Haemostasis, 2007
- A vitamin K epoxide reductase complex subunit‐1 (VKORC1) mutation in a patient with vitamin K antagonist resistanceJournal of Thrombosis and Haemostasis, 2005
- Effect ofVKORC1Haplotypes on Transcriptional Regulation and Warfarin DoseNew England Journal of Medicine, 2005
- Yin and Yang of MCP-1Circulation Research, 2005
- Inflammation, Atherosclerosis, and Coronary Artery DiseaseNew England Journal of Medicine, 2005
- VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulationThrombosis and Haemostasis, 2005
- Pharmacodynamic resistance to warfarin associated with a Val66Met substitution in vitamin K epoxide reductase complex subunit 1Thrombosis and Haemostasis, 2005
- C-Reactive Protein Promotes Monocyte Chemoattractant Protein-1—Mediated Chemotaxis Through Upregulating CC Chemokine Receptor 2 Expression in Human MonocytesCirculation, 2004
- The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumonThrombosis and Haemostasis, 2004
- Contribution of non-cardiomyocyte apoptosis to cardiac remodelling that occurs in the transition from compensated hypertrophy to heart failure in spontaneously hypertensive ratsClinical Science, 1999